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Traumatic brain injury (TBI) is the leading cause of death and disability in individuals 
under 45. Individuals who survive TBI may be disabled for the rest of their lives and suffer from 
cognitive, physical, social and financial problems. Following TBI it has been shown that 
astrocytic gene expression of many proteins, including glial fibrillary acidic protein (GFAP), 
increases. These “reactive” astrocytes are thought to have both beneficial and detrimental effects 
on neuronal survival and function. The current study uses an in vitro model of injury which 
grows astrocytes on deformable silastic membranes to allow for dynamic stretch of cultured cells 
and tries to mimic the stress and strain on brain tissue that is seen following human TBI. The 
current study of reactive gliosis is two-fold: 1) a stretch injury response curve (3, 4, 5, 6, and 
7mm at 24 and 48 hr after injury) and 2) a stretch injury time course (0.25, 2, 6, 24 and 48 hr 
after injury at 6mm). Glial fibrillary acidic protein expression, a marker for reactive gliosis, was 
measured by Western blotting and immunofluorescence techniques. Immunofluorescence 
showed that GFAP expression increased and astrocytes became more reactive as the magnitude 
of stretch injury increased, and that cell morphology and GFAP expression varied at different 
times after injury. Western blotting was inconclusive as it was difficult to discern differences in 
GFAP expression between samples. It can be concluded that the stretch-injury model is a useful 
way to injure astrocytes and can be used in the future to mimic TBI in the “dish.”
2Introduction
Traumatic brain injury (TBI) is the leading cause of death and disability for individuals 
under the age of 45 years. It is estimated that every year in the United States at least 1.4 million 
people sustain a TBI, and 50,000 Americans die from the condition (“Facts about,” 2006). The 
major causes of TBI are vehicular and bicycle accidents, falls, violence, and recreational 
activities (Kreutzer et al., 1997). One of the highest risk factors for having a TBI is having had a 
previous injury because people with TBI may have problems controlling impulses and in 
thinking abilities which can lead to unsafe behaviors (Christensen, 2001a). According to 
Christensen (2001a), children from families with low socioeconomic backgrounds are at a 
greater risk for TBI, most likely due to a lack of access to preventative measures such as bicycle 
helmets and a shortage of safe play areas. Individuals who use alcohol and/or drugs and those 
with attention deficit disorders are also at a greater risk. It has also been found that boys are 
twice as likely as girls to sustain a TBI. There are two age groups that have the highest incidence 
for sustaining TBI: children/young adults and the elderly (Christensen, 2001a). The major cause 
for TBI within these age groups is falling. According to Kreutzer et al. (1997), within the young 
age group those most greatly affected are aged 15 to 24 and then aged 5 to 14. In 1993, 39% of 
all people treated at major trauma centers for brain injury were between the ages of 16 and 25 
(Kreutzer et al., 1997).
Individuals who survive TBI may be disabled for the rest of their lives and suffer from 
low work or school productivity, social problems, and financial strains. (“Facts about,” 2006) 
According to Kreutzer et al. (1997), “Estimates of unemployment following severe injury range 
as high as 70% within the first 7 years.” Family adjustment problems are also common as the 
injured individual may not act like the same person as before and may now have special needs.
3This can lead to the problems of frustration, depression, and social isolation in both the victim 
and caretakers. It has also been discovered that alcohol use is a “common factor among persons 
with brain injury, relevant to both cause of injury and post-injury adjustment” (Kreutzer, 1997).
“The most common, persistent, and problematic issues occurring after TBI are learning 
and behavioral problems directly related to the brain injury” (Christensen, 2001b). These 
problems are due to neurological complications. The first of these is post-concussion syndrome 
which is characterized by headache, dizziness, memory loss, frequent mood changes, sound 
sensitivity, difficulty concentrating, disinhibition, depression, and fatigue (Christensen, 2001b). 
Most of these symptoms subside or improve, but others may linger. Headaches are another 
problem and include migraines, tension headaches, and head and neck pain associated with 
whiplash from the injury. Seizures are not uncommon after TBI, but persistent seizures are 
uncommon and can develop into posttraumatic epilepsy (Christensen, 2001b). According to 
Christensen (2001b), the risk for developing posttraumatic epilepsy is 5-7% in closed head TBI 
and 11% in severe closed head TBI. However, the risk is 35-50% if the TBI is due to an open 
wound. Risk factors for post-traumatic seizures include focal injuries, wounds involving 
penetration of the dura mater, and severe rather than mild TBI (Christensen, 2001b). If an 
individual meets these criteria he or she is usually put on an antiepileptic drug. A very rare 
complication of TBI is hydrocephalus which is due to increased amounts of cerebrospinal fluid 
under increased pressure (Christensen, 2001b). This can occur when the brain shrinks in size 
after TBI due to the loss of many neurons. Cerebrospinal fluid takes up the excess space and 
only becomes a problem when the pressure increases. For individuals with hydrocephalus, a 
ventriculoperitoneal shunt can be inserted to drain the cerebrospinal fluid from the ventricles into 
the abdomen to relieve the pressure (Christensen, 2001b).
4Motor impairment is another consequence of TBI, but it usually is not severe in most 
patients. Most severe TBI patients will move and react more slowly than prior to the injury but 
they will still retain function. Patients who have endured comas lasting a few weeks or more will 
usually have some type of obvious motor impairment, but a substantial amount of improvement 
can be made through physical therapy (Christensen, 2001b). High muscle tone is an issue for 
most severe TBI cases, but it can also be helped using physical therapy techniques such as 
stretching, splinting, and positioning of the limbs and body (Christensen, 2001b). Eating and 
drinking can also pose a problem after TBI for several reasons. First, the individual may have 
difficulty swallowing due to weakness and/or lack of coordination of the muscles involved in 
chewing and swallowing. This can lead to taking a very long time to eat and also having food go 
down the trachea instead of the esophagus. Feeding tubes can be used if the individual cannot 
eat at all or a special diet can be implemented until he or she regains sufficient muscle control to 
eat normal food (Christensen, 2001b).
In the weeks following TBI, hormone regulation may be affected since the brain regulates 
the structures which, in turn, regulate hormones (Christensen, 2001b). This may cause 
symptoms associated with thyroid problems, cessation of menstruation in women for 3-6 months, 
and/or too much or not enough urine production (Christensen, 2001b). The immune system may 
also be weakened after TBI and secondary infections such as pneumonia or oral thrush may 
manifest (Christensen, 2001b).
TBI can lead to an increased incidence of psychiatric issues which include depression and 
psychoses and also disinhibition, inattention, and impulsivity which can lead to secondary 
attention-deficit/hyperactivity disorder (Christensen, 2001b). Secondary AD/HD affects many
5individuals, especially children, who have had a moderate to severe TBI. Stimulants such as 
Ritalin or Dexedrine can be given to improve attention (Christensen, 2001b).
“Memory problems have been identified as the most common and most persistent 
consequence of TBI” (Brady, 2001). Declarative memory—or memory for facts and 
experiences—is much more likely to be impaired than procedural memory, which is the memory 
for motor skills, conditioning, and that which is subconsciously retrieved (Brady, 2001). In 
declarative memory, old memories are often unaffected by TBI, but the retrieval of new and 
short-term memories and the learning of how to do new things is often hindered by TBI. (Brady, 
2001)
Difficulty with the visual system is also a likely consequence of TBI because swelling, 
bleeding, or other sources of pressure put force on the cranial nerves—in particular the 
oculomotor (III), the trochlear (IV), and the abducens (VI). Problems that may result are ptosis 
(drooping of the eyelid), pupil dilation which causes difficultly in seeing things that are near, and 
strabismus which occurs when one eye is deviated upward, inward, and/or outward so that both 
eyes cannot focus on the same spot resulting in double vision (Brady, 2001). Usually these 
problems get better in the days following the injury due to decreased swelling and therefore 
decreased pressure on the cranial nerves. (Brady, 2001)
Visual perception problems may also arise from TBI. An afflicted individual may 
experience blind spots, but this is very uncommon in TBI as it is a consequence of localized 
injury to the visual primary zone (Brady, 2001). A more common problem is not being able to 
tell where one object ends and another begins, not being able to assimilate many features to 
recognize a whole, or not being able to recognize an object if it is at an unfamiliar angle or in 
silhouette (Brady, 2001). These problems worsen when the visual field has many stimuli such as
6in a crowded area or a busy street. Visual-auditory integration problems may arise which lead to 
difficulty in naming something that is seen and in reading. Visual-motor integration is the ability 
to “see” a route or a picture and then carry it out (Brady, 2001). Complications in this area can 
manifest as problems in moving through a space or writing and drawing. Another uncommon 
problem that is associated with damage to the right side of the brain in the tertiary zone of the 
sensory unit is unilateral neglect (Brady, 2001). This phenomenon is when an individual 
neglects objects on the left side of the body and even the left side of the body itself. This can 
cause problems in reading, navigating the body through spaces, and even crossing the street due 
to neglecting to look left. (Brady, 2001)
One of the most common consequences of closed head TBI injury is executive function 
deficits. Executive function is a term for “the cluster of cognitive processes that are needed for 
organized, goal-directed behavior” (Brady, 2001). These functions are controlled by the frontal 
lobes which are responsible for sensory output. In closed head TBI the frontal lobes are almost 
always involved which affects them and also their pathways with almost all other regions of the 
brain due to the stretching and tearing of neuronal axons (Brady, 2001). The frontal lobe is 
essential in impulse control which allows a person to keep impulses from distracting them from 
working towards an end goal or saying or doing something inappropriate. It is also important in 
abstract thinking. Individuals with TBI often think in concrete terms and are unable to grasp 
abstract ideas such as innuendo, sarcasm, humor, symbolism, and other forms of indirect 
communication (Brady, 2001). These individuals also usually have difficulties with frustration 
control because they cannot grasp the concept of waiting for something if it does not come 
immediately. They may also have difficulties with flexibility, creativity, and initiation of new 
ideas especially in problem solving and daily living. Lastly, TBI sufferers may lack empathy,
7insight, and responsibility because they cannot evaluate how their actions affect others and may 
therefore be seen as selfish and uncaring (Brady, 2001). Therefore, frontal lobe injury has a 
large impact on an afflicted individual and can make social interactions awkward and difficult.
Speech and language problems may also arise after TBI and vary with the severity of the 
injury and the way in which the brain moved within the skull. If the brain just hit one side of the 
skull, speech and language problems will most likely be less than if the brain rebounded off one 
side of the skull and hit another side and if bleeding and edema were involved (Schoenbrodt, 
2001). These types of problems can be transitory, but many can last for years or be permanent. 
Speech issues can occur in any of the three phases of speech: respiration, speech sound 
production, and vocal (Schoenbrodt, 2001). Speech problems are less common than language 
problems because language is closely related to cognitive and executive functions which may 
also be damaged. Language difficulties can be in the ability to understand others’ language, the 
ability to use language to express oneself, or in both of these areas (Schoenbrodt, 2001).
Lastly, behavioral problems may be seen in TBI victims, especially those who otherwise 
seem to be recovered, in particular if they suffered damage to the frontal lobe. There are two 
types of behavioral problem patterns: over stimulation and under stimulation. If an individual is 
over stimulated he or she will most likely display “distractibility, irritability, agitation, 
hyperactivity, impulsivity, disinhibition, social inappropriateness, and aggression” (Tucker, 
2001). If an individual is not stimulated enough, he or she will usually display “apathy, lack of 
motivation and initiation, shyness or social withdrawal, depression, and physical complaints such 
as stomachaches, fatigue, or general malaise” (Tucker, 2001). A person with TBI can exhibit 
either one of these behavioral patterns can fluctuate between the two (Tucker, 2001).
8There are several indicators that are used to assess the severity of TBI, and depending on 
the severity of the case, it may be conjectured which, if any, of the aforementioned problems 
may arise in the afflicted individual. The severity of the brain injury can be classified as mild, 
moderate, or severe and can be measured by three means: the Glasgow coma scale, the duration 
of the coma, and the length of the posttraumatic amnesia (Christensen, 2001a). This 
classification is important as it allows the patient and doctors to know what to expect and look 
for as well as what treatment should be given. Traumatic brain injury severity is also linked to 
age as children and adolescents usually fair much better than adults, but older adolescents do 
better than younger children (Christensen, 2001a). This can be attributed to the fact that TBI 
affects learning, and older adolescents have already learned many things that younger ones have 
not. It can also be due to the different physical and chemical properties of the young brain. 
Secondary injuries such as hypoxic ischemic injury and stroke will also increase the severity of 
the brain injury (Christensen, 2001a).
The damage that is incurred by the neurons and astrocytes as well as other glial cells may 
result in cell death which causes the brain to lose mass. This leaves excess space which is then 
occupied by enlarged ventricles that have an increased amount of cerebral spinal fluid (Bigler, 
1997). Using brain imaging techniques the ventricles can be viewed over the ensuing months, 
and it can be determined in what areas of the brain the tissue loss has occurred (Bigler, 1997). 
This allows health specialists to surmise which symptoms a patient may display.
The brain injuries that cause the aforementioned problems in humans can be separated 
into immediate and delayed injuries. Immediate injuries include contusions (bruises) from an 
impact and diffuse axonal injury in which the axons of nerves are severed due to the shearing 
forces of the brain trauma (Christensen, 2001a). Delayed injuries include bleeding, herniation
9syndrome, edema, and damage from the neurotoxic cascade (Christensen, 2001a). Depending on 
the severity of these injuries and the time in which they are treated, treatment may be successful 
with the exception of treatment for the neurotoxic cascade. Currently there are no effective 
treatments to alter the neurotoxic cascade.
Bleeding is caused by blood vessels being tom due to trauma and can occur within the 
brain itself, into the ventricles, into the spaces surrounding the brain, between the skull and the 
dura mater, under the dura mater, or under the arachnoid layer into the cerebrospinal fluid 
(Christensen, 2001a). When bleeding occurs pressure is put on the brain because there is not 
enough room in the closed skull for the extra blood. This may lead to reduced blood flow 
through capillaries which can lead to neuronal injury due to lack of oxygen and blood flow 
which is termed hypoxic ischemic injury (Christensen, 2001a).
Herniation syndrome occurs when a localized mass or lesion, usually blood or swollen 
brain tissue, pushes on the brain and forces it to deform to fit into another intracranial space.
This can cause further localized brain injury and stroke (Christensen, 2001a). Edema is the 
swelling of the brain which can cause increased intracranial pressure resulting in the same 
problems as bleeding (Christensen, 2001a). In most severe TBI cases an intracranial pressure 
monitor is temporarily surgically implanted in the head so that increases in intracranial pressure 
can be detected and treated early (Christensen, 2001a).
Damage from the cellular neurotoxic cascade is a new focus in treating TBI but there is 
still much that is unknown so research is focused on ways to modify or prevent the secondary 
injuries due to this cascade pathway (Christensen, 2001a). At the cellular level, neurons have 
been the main focus of TBI research, and the supporting glial cells have been neglected.
However, more attention has been directed toward the roles of glial cells, specifically astrocytes,
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in the body’s response to TBI. These glial cells constitute approximately 40% of the volume of 
brain tissue and outnumber neurons ten to one (Walz & Juurlink, 2002). In the uninjured brain, 
astrocytes have many diverse roles. First, these glial cells are an integral part of the blood-brain 
barrier. Astrocytes have cytoplasmic extensions that end in expanded processes that wrap 
around the endothelial cells of the capillaries found in the brain (Martini, 2004). These cells 
secrete chemicals which are necessary for maintaining the special permeability characteristics of 
the capillary endothelial cells (Martini, 2004). If the astrocytes are damaged and cease 
stimulating these endothelial cells, the blood-brain barrier does not work properly. When this 
occurs, hormones and other chemicals can exit the blood and enter the interstitial fluid which 
may damage neurons (Martini, 2004). These glial cells are also an important part of the physical 
structuring of the brain. Astrocytes create a three-dimensional framework for the CNS because 
they contain many microfilaments that extend across the cell body and its processes which 
provide structure (Martini, 2004). In the embryonic brain, astrocytes “appear to be involved in 
directing both the growth and interconnection of developing neurons” (Martini, 2004). They 
also are essential in repairing damaged neural tissue since neurons seldom regain normal 
function after injury. In this case, astrocytes move to the site of injury to make structural repairs 
that stabilize the tissue by isolating the damaged area, thereby preventing further injury. (Martini, 
2004)
Another very important role of astrocytes is controlling the interstitial environment by 
adjusting its composition. Astrocytes have a variety of ways in which they accomplish this, 
including regulating the concentrations of sodium ions, potassium ions, and carbon dioxide, 
providing a system for transport of nutrients, ions, and dissolved gases between capillaries and 
neurons, controlling the volume of blood flow through capillaries, absorbing and recycling
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certain neurotransmitters, and releasing chemicals that enhance or suppress communication 
across synaptic terminals (Martini, 2004). Astrocytes are able to accomplish these duties 
because they have a diverse collection of receptors which include those for neurotransmitters, 
glutamate, acetylcholine, ATP, and histamine as well as voltage-gated calcium ion channels 
(Floyd & Lyeth, 2007). They also provide metabolic support to neurons by supplying them with 
nutrients such as glucose and lactate. Astrocytes are able to do this as they allow glutamate to 
enter through their processes contacting capillaries, and then they can deliver glutamate to 
neurons for the pentose phosphate pathway (Walz & Juurlink, 2002). Astrocytes also store 
energy in the form of glycogen which can be broken down into lactate and supplied to neurons 
when there is a shortage of glutamate (Walz & Juurlink, 2002). Astrocytes are able to 
communicate and alter neuronal signaling too, and accomplish this through the release of 
glutamate and ATP (Floyd & Lyeth, 2007).
When an injury first occurs, neurons release large quantities of glutamate and other 
excitatory neurotransmitters due to the triggering of many action potentials by nonspecific 
depolarization (Madikians & Giza, 2006). This causes an efflux of potassium into the 
extracellular space and also the opening of neuronal ligand-gated calcium channels (Madikians 
& Giza, 2006). Calcium travels through these channels into the neuron which can cause 
“overstimulation of phospholipases, plasmalogenase, caplains, protein kinases, guanylate 
cyclase, nitric oxide synthetase, calcineurins, and endonucleases” which in turn cause 
overproduction of free radicals, disruption of cytoskeletal organization, and activation of 
apoptotic signaling (Madikians & Giza, 2006). This does not always result in cell death, but it 
does affect the metabolic machinery of mitochondria so that they are unable to produce energy 
when needed which can then lead to cell death (Madikians & Giza, 2006).
Cell death can trigger secondary neuronal injury including axonal swelling, loss of 
membrane integrity, and perpetuated free radical injury (Hatton, 2001). Cerebral ischemia can 
then trigger “chemical activation of mediators that perpetuate continued neuronal death despite 
correction of the initiating event” (Hatton, 2001). Ischemia, toxic insult, and physical insult can 
then all cause neuronal necrosis to occur. Necrosis is characterized by “cellular swelling and 
membrane disruption in conjunction with lysis of nuclear chromatin” (Hatton, 2001). This 
allows the contents of the cells, including ions and glutamate, to spill into the extracellular fluid 
and cause inflammation and excitotoxicity in other cells which allows the cycle of cell death to 
continue which can then lead to large areas of tissue death (Hatton, 2001). These signs of 
delayed axonal injury can begin within 2 to 3 hours post-injury and continue for at least 24 
hours. (Hatton, 2001)
In response to injury and the reactions of neurons to injury, astrocytes swell, change their 
ion channel pattern, their ionic composition, and increase their production of growth and trophic 
factors within minutes (Walz & Juurlink, 2002; Liberto et al., 2004). “If local cerebral blood 
flow falls below 20% of normal, energy depletion occurs in surrounding cells, and ion 
homeostasis is subsequently lost” which results in anoxic depolarization (Walz & Juurlink, 
2002). The swollen astrocytes exhibit “pale and watery cytoplasm and dissociation of filament 
bundles” which is not to be confused with the hypertrophy visible in the reactive astrocytes of 
the delayed response stage (Walz & Juurlink, 2002). Astrocytes will also swell within thirty 
minutes if exposed to glutamate, and they will swell within seconds of exposure to excess 
potassium (K+) as they clear this molecule and other anions from the extracellular space (Walz & 
Juurlink, 2002).
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In the normal extracellular space K+ levels are 1 mM with the passage of one action 
potential and, during increased stimulation or during seizure, these levels may reach a ceiling 
value of 12 mM (Walz & Juurlink, 2002). However, during an injury such as one caused by 
hypoxia/ischemia, trauma, or hypoglycemia, K+ levels may increase to 25 mM (Walz & Juurlink, 
2002). When spreading depression waves occur, K+ concentration levels can transiently reach 
30-80 mM (Walz & Juurlink, 2002). Potassium ion increases that are higher than 5 mM lead to 
hyperexcitibility and affect the efficacy of synaptic transmission (Walz & Juurlink, 2002). 
Astrocytes help in removing excess K+ from the extracellular space using two mechanisms.
They can remove it via current loops through the astrocytic syncytium which allows one K+ ion 
to enter as another leaves at a distant site from the active neurons, or they can remove K+ by 
uptake and transfer into adjacent astrocytes (Walz & Juurlink, 2002).
The swollen astrocytes are most likely a large component in the increased intracranial 
pressure seen after TBI. This is due to “alterations in ion-transport mechanisms that leads to 
osmotically obligated water entry” (Floyd & Lyeth, 2007). The astrocytic response of swelling 
also negatively impacts neurons as swollen astrocytes take up extracellular space and restrict 
exchange with the blood vessels. The decreased extracellular space causes an increase in 
excitatory substances such as K+ and glutamate which will also damage neurons (Walz & 
Juurlink, 2002). The astrocytes eventually decrease in size through a regulatory volume decrease 
in which amino acids are released. The astrocytes then depolarize as depolarized neurons release 
K+ and glutamate which in turn causes the astrocytes to release intracellular calcium ions (Walz 
& Juurlink, 2002). Since injured neurons release an excess amount of glutamate, astrocytes 
remove it from the extracellular space and convert it into glutamine which can then diffuse out of 
the cell and is taken back up by the presynaptic neuron to be made back into glutamate (Floyd &
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Lyeth, 2007). However, in TBI the excess glutamate in the extracellular space can result in 
excitotoxicity due to over activation of “ion-channel linked and G-protein linked glutamate 
receptors” (Floyd & Lyeth, 2007).
The delayed response phase begins within days of the trauma and is when reactive 
astrocytes appear. These reactive astrocytes are marked by “hypertrophy, increase in filaments 
and in processes, changes in the expression of enzymes, different extracellular matrix 
composition, and different secretion products” (Walz & Juurlink, 2002). If neuronal loss is also 
occurring, proliferation of astrocytes can be seen. Reactive astrocytes respond differently 
depending if the injury is diffuse or focal, and within the focal injuries there are two types of 
response astrocytes: local and remote (Walz & Juurlink, 2002). Both the local and remote 
response astrocytes express an increased amount of glial fibrillary acidic protein (GFAP) which 
is an 8-9 nm intermediate filament in the cytoskeletal protein family (Eng et al., 2000; Walz & 
Juurlink, 2002). This is permanent in the local area astrocytes but returns to normal levels in the 
remote area astrocytes. Hypertrophy is also similar as the astrocytes in the local area stay larger 
and the ones in the remote areas return to normal size (Walz & Juurlink, 2002). Vimentin is also 
expressed in the local astrocytes but is not expressed at all in the remote astrocytes (Walz & 
Juurlink, 2002). These factors support that local area response astrocytes serve different 
purposes than remote area astrocytes and are triggered by different mechanisms (Walz & 
Juurlink, 2002).
These reactive astrocytes have been found to have both positive and negative effects on 
neurons. The remote response astrocytes have a neuroprotective effect which may be due to “the 
secretion of neurotrophic factors, such as nerve growth factor, basic fibroblast growth factor, 
neurotrophin 3, and ciliary neurotrophic factor” (Walz & Juurlink, 2002). They also help to
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protect neurons as they clear K+ from the extracellular space even though they cannot do this as 
well as uninjured astrocytes. However, reactive astrocytes can also be detrimental as there is 
evidence that they inhibit axonal regeneration which may be a result of proteoglycan expression 
(Walz & Juurlink, 2002). The proteoglycans are only expressed by astrocytes that “demarcate 
the borders of cysts and the interface between activated macrophages-microglia within the 
necrotic core area and surrounding reactive astrocytes” which suggests that the local response 
astrocytes are responsible for the negative effect on neuron repair and axonal regeneration (Walz 
& Juurlink, 2002). This process serves to create what is known as a “glial scar” which marks the 
border of the damaged area and prevents its spread into nearby tissues (Floyd & Lyeth, 2007; 
Walz & Juurlink, 2002).
It is known that reactive astrocytes increase in number in the area around a wound 
following TBI through mitotic division (Takamiya et al., 1988). It is has also been shown that 
reactive astrocytes are characterized by rapid GFAP synthesis which is “directly involved in cell 
resilience and the maintenance of tissue integrity” (Eng et al., 2000). Glial fibrillary acidic 
protein is vital in astrocyte-neuronal interactions and in “modulating synaptic efficacy in the 
CNS” (Eng et al., 2000). It is also important in altering the motility and shape of astrocytes by 
providing astrocytic processes with structural stability which is particularly important following 
TBI (Eng et al., 2000). The rapid GFAP synthesis occurring in reactive astrocytes after injury 
can be visualized by immunostaining with GFAP antibody or shown by an increase in protein 
content using methods such as Western blotting (Eng et al., 2000). Hypertrophy and hyperplasia 
might account for the increase in GFAP staining following injury due to an associated increase in 
size and therefore the number of GFAP-positive cells (Kraig et al., 1991).
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There are many different ways to simulate TBI in the lab, which include in vivo and in 
vitro models. The four most commonly used in vivo methods of injury include fluid percussion, 
impact acceleration, controlled cortical impact, and weight drop models (Kulbatski et al., 2008). 
In vivo models are useful in studying the effect of injury at the organismal level, but they do not 
allow for easy study of individual cell types such as neurons and glial cells (Ellis et al., 1995). 
However, using in vitro models these cells and their responses to injury can be observed with 
greater ease and accuracy. In in vitro models concerning the effects of injury on astrocytes, the 
cells plated can be purely astrocytes, co-cultures of astrocytes and neurons, or co-cultures of 
astrocytes and microglia, depending on the goals of the research. The cells used for these 
cultures are usually obtained from young uninjured animals, and are then injured in vitro using 
techniques such as scraping the cells, exposing the cells to chemicals such as NMDA or 
glutamate, or stretching the cells (Wu & Schwartz, 1998). All of these models have their pros 
and cons in respect to what is to be measured or observed, the type of injury that is to be 
examined, and the ease of use.
In order to injure the astrocytes in our experiment, we used a stretch-induced injury 
model developed by E.F. Ellis and collaborators. According to Ellis et al. (1995), the purpose of 
this model was to “produce simple, reliable, and consistent injury of large cell populations grown 
in culture” that “inflicts mechanical forces that are relevant to those which might occur in vivo.” 
This model uses stretch to injure cells which is “a key component in the acceleration/deceleration 
type of closed human TBI” (Floyd & Lyeth, 2007).
In this model the cells of interest are plated on Flex Plates which have wells with 
deformable silastic bottoms. The cells are injured by deforming the silastic membranes that they 
are sitting on using pressurized air. The air pressure and the duration of the pulse of air delivered
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to the wells is regulated by the Cell Injury Controller. Once the air pulse is delivered to the well, 
the air between the well and adapter is vented out which allows a rapid deformation and rebound 
of the silastic membrane (Ellis et al., 1995). Different levels of stretch can be achieved by 
varying the air pressure delivered to the well. The controller can be calibrated by seeing how far 
the deformed membrane pushes a sliding plastic pointer mounted on a ruler at a certain air 
pressure. Once this is determined the cells can be measured at known levels of stretch by dialing 
in the desired pressure on the Cell Injury Controller (Ellis et al., 1995).
This model has been used in many diverse experiments which include those examining 
mitochondrial membrane potential and cellular ATP in astrocytes and neurons (Ahmed et al., 
2000), the effects of 17β-estradiol on intracellular calcium changes and neuronal survival after 
injury (Lapanantasin et al., 2006), the effects of injury on calcium and sodium in cortical 
astrocytes (Floyd et al., 2005), and activation of extracellular signal-regulated kinase in 
astrocytes (Neary at al., 2003). The efficacy of this in vitro model of TBI has been shown as the 
injured cells exhibit many of the following known signs of injury which include “intracellular 
lesions to the mitochondria, Golgi, and cytoskeletal elements in astrocytes and neurons, and 
increases in astrocyte and neuronal permeability,” and rises in intracellular calcium and sodium 
levels in astrocytes (Ellis et al., 1995).
As it has been demonstrated, TBI has profound effects on individuals and society, but 
there still is a great deal to discover, especially on the cellular level. Due to the diverse effects 
that astrocytes have on the injured brain and the recent attention that they have been receiving, 
more research is needed to further understand their role in TBI. According to Floyd and Lyeth 
(2007), further research is needed to uncover the mechanisms mediating cell damage after TBI 
and also to define the time course of astrocyte damage after injury.
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In the current study, we used the stretch-induced cell injury model to injure astrocytes at 
increasing levels of stretch and at increasing time intervals. Since GFAP is upregulated due to 
astrocyte injury, it was used as a marker to determine astrocyte response to different levels of 
stretch as well as to astrocyte response at increasingly longer times after injury. Glial fibrillary 
acidic protein was assessed using immunofluorescence and Western blotting. It was 
hypothesized that GFAP expression would increase with higher levels of stretch and be 
detectable at 6-24 hours after injury.
Methods
1. Astrocyte Cell Culture 
Dissection
Astrocytes were derived from 1- 3 day postnatal mice (Hilltop Lab Animals, Scottdale, 
PA) that were housed in the Lynchburg College animal facility with a 12 h light/12 h dark cycle 
and food and water provided ad libitum. The mice were sacrificed by rapid decapitation and 
their heads were rinsed twice in culture dishes containing 70% ethanol to remove debris. The 
heads were transferred to a culture dish of dissecting medium (Hanks Balanced Salt Solution 
without Ca++ or Mg++ (Fisher Scientific, Rockford, IL) supplemented with sucrose, dextrose, and 
Hepes) on ice in a horizontal flow hood under a dissection microscope.
Micro dissecting forceps were used to peel the skin away from the skull and the skull 
away from the brain. The brain was removed and placed in another dish of dissecting medium, 
placed ventral side up, and the meninges were peeled away. It was then turned over and the 
dorsal meninges were then removed. Next, the hemispheres were pulled open and the basal 
forebrain, hippocampus, and striatum were removed and the cortices were transferred to a third
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dish with dissecting medium. The cortices were mechanically minced with forceps and added to 
a 15 ml centrifuge tube of thawed 0.025% trypsin in dissecting media using a transfer pipette. 
The tissue was incubated in a 37 °C water bath for 20-30 minutes to start the initial breakdown 
of tissue to a single cell suspension.
Initial Cell Plating
The trypsin tube containing the cortical hemispheres was centrifuged at 1000 rpm for 5 
minutes, and the supernatant was aseptically decanted and replaced with a small amount of 
plating medium (Modified Earle’s Media supplemented with glucose (final concentration 
20mM), 10% fetal bovine serum, 10% calf serum, L-glutamine (2mM), penicillin (50 IU/ml)- 
streptomycin (50µg/ml) and epidermal growth factor (10 ng/ml)). The mixture was triturated 
with a medium bore pipette followed by a small bore pipette until homogeneous and then diluted 
with plating medium (~1.2 cortical hemispheres/10 ml). Ten milliliters of cell mixture was 
plated into T75 flasks and incubated at 37 °C with 5% CO2/95% air.
Subculturing Astrocytes onto Flex Plates
After the astrocytes became near contact-inhibited (~1 week) they were subcultured onto 
25 mm silastic membranes of six-well Flex Plates (Flexcell International, NcKeesport, PA) at a 
density of 4xl05 cells/ml. To subculture the cells, the flasks were rinsed twice with Hanks 
Balanced Salt Solution (HBSS), exposed to 0.25% trypsin in HBSS for one minute, and then 
incubated with fresh HBSS at 37 °C for five minutes to loosen the cells. The cells were knocked 
off the flask and then centrifuged at 1000 rpm for 5 minutes at room temperature. The 
supernatant was removed and replaced with plating medium and the mixture was triturated until 
homogeneous. Five ml of plating medium with was added to the cells for every flask 
subcultured. The cells were counted with a hemocytometer and then diluted with plating
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medium to 4xl05 cells/ml before plating onto Flex Plates. After growth had become confluent 
the cells were treated with 9 µM cytosine β-D-arabinofuranoside for 4-7 days to reduce the 
microglia population in the astrocyte enriched cultures. After this treatment, the cultures were 
fed with growth media (Modified Earle’s Media supplemented with 10% calf serum, L- 
glutamine (2mM), and penicillin (50 IU/ml)-streptomycin (50pg/ml)).
2. Astrocyte Cell Injury 
Cell Injury
The day before injury the growth media in the Flex Plates was replaced and the next day 
the cells were injured using a Model 94A Cell Injury Controller Device (Commonwealth 
Biotechnology, Richmond, VA) in a horizontal flow hood. For the injury response study, cells 
were injured at 3, 4, 5, 6, and 7 mm of stretch (Appendix A) and one well was uninjured as a 
control. After injury the cells were allowed to recover in the incubator at 37 °C with 5% 
CO2/95% air for either 24 or 48 hours. For the time course study, all wells of a plate except for 
the control were either injured at 6 or 6.5 mm of stretch, and evaluated at 15 minutes, 2, 6, 24, or 
48 hours after injury. After each injury time point, the cells were returned to the tissue culture 
incubator.
3. GFAP Expression Evaluation 
Western Blotting
To isolate the proteins, the astrocytes were rinsed twice on ice with cold PBS prior to 
manually rocking with radioimmunoprecipitation (RIPA) buffer (Boston BioProducts,
Worcester, MA) for 5 minutes. The wells were scraped, triturated, and the buffer was pipetted
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into centrifuge tubes. The lysates were centrifuged (14,000 rpm, 30 minutes, 4°C) to remove 
cellular debris. The supernatants were collected, the protein concentrations were determined 
using the BioRad assay (BioRad, Hercules, CA) with a bovine serum albumin standard, and then 
the volume of sample containing 2.5 µg of protein was calculated from the standard curve 
(Appendix B). All remaining samples were aliquoted and frozen at -20°C until needed.
After determining the protein concentration of each lysate, 2.5 µg protein was separated 
on a 10-well 4-12% Bis-Tris mini gel (Invitrogen) with a MOPS running buffer (Invitrogen) 
under reducing conditions. The proteins were loaded at 2.5 (µg so that the total volume of 
sample, dH2O, loading buffer, and reducing agent loaded was 25 µl (Appendix C) with SeeBlue 
standard molecular weight markers (Invitrogen). After the gel was loaded it was run at a 
constant 200 V for 50 minutes. The proteins on the gel were transferred to nitrocellulose paper 
using 30 V for 1 hour in the XCell SureLock Mini-Cell. The blots were rinsed twice with PBS, 
dried on filter paper and stored at -20°C until needed.
To complete the Western blotting, the blots were brought to room temperature and 
rehydrated with PBS. They were blocked with blocking solution (0.05% Tween-20, 5% non-fat 
dry milk in PBS) for one hour at room temperature and then the primary antibody, rat a-GFAP 
(1:7500 in blocking solution; Invitrogen) was applied for ~20 hours while rocking at 4°C. The 
next day, the blots were rinsed three times with blocking solution for five minutes with rocking 
at room temperature, and then 3 more rinses were repeated using PBS. The secondary antibody, 
donkey a-rat horseradish peroxidase (1:10,000 in PBS; Invitrogen) was applied for one hour with 
rocking at room temperature. The blots were washed four times with PBS with rocking for five 
minutes and then were exposed for one minute to SuperSignal West Pico Chemiluminescent 
(Pierce, Rockford, IL) while manually rocking to ensure entire coverage. The blots were then
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placed in a plastic development sheet in a cassette and exposed to film for 5-60 seconds in the 
dark room.
Immunofluorescence
To fix the cells they were rinsed twice with phosphate buffered saline (PBS), pH 7.4, 
exposed to 4% paraformaldehyde in PBS for 15 minutes, and then rinsed twice again with PBS. 
Cells were stored in PBS at 4°C until needed.
To prepare for the addition of the GFAP antibody, the cells were rinsed twice with PBS 
and then they were permeabilized with 2N HC1/0.1% Triton-X 100 for 30 minutes at 37°C. Two 
5 minute washes with sodium borate while rocking were completed to neutralize the acid and 
then the cells were rinsed 3 times with PBS. Nonspecific binding of the primary antibody was 
blocked by rocking the cells with 4% horse serum for one hour at room temperature. The 
primary antibody, rabbit α-GFAP (1:500 in blocking solution; Dako, Carpinteria, CA), was put 
on the cells and rocked for 20 hours at 4°C. The following day, the cells were washed three 
times with PBS for 5 minutes while rocking. The fluorescent secondary antibody, Alexa Fluor 
488nm goat anti-rabbit IgG (1:750 in PBS; Invitrogen, Camarillo, CA) was put on the cells for 
one hour in the dark at room temperature while rocking. Under dimmed lights, the cells were 
rinsed three times with PBS for five minutes while rocking.
In order to view the cells under a fluorescent microscope (Olympus CK40), the bottom of 
the Flex Plate wells were popped out into PBS, the curved edges of the membrane were 
removed, and they were mounted on slides with Fluoromount-G (SouthernBiotech, Birmingham, 
AL). Fluorescent pictures were taken with an Olympus camera attached to the fluorescent 
microscope and captured with PictureFrame software.
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Results
1. Astrocyte Response to Magnitude of Injury 
Western Blotting
The Western blots for injury level at 24 and 48 hours showed bands right above the 
molecular weight marker of 51 kDa (blue line in Figs. 1 and 2). There was also only one band 
for each sample with no apparent shadows above or below the bands. In Fig. 1, the lanes 
containing the 7 mm sample and the second run of the control in blot (a) have very light bands, 
and this also occurred in the lanes containing the 6 mm and 7 mm samples in blot (b). In blot (a) 
at 24 hours it appears that the sample at 3 mm and the second 5 mm sample are the largest bands. 
Also, the first band from the 5 mm sample appears to be smaller than the second band from the 
same 5 mm sample. In blot (b) at 24 hours the first control band appears to be the largest band, 
but this band is larger than the second control band which was taken from the same sample.
Fig. 1. Western blots of GFAP expression in astrocytes 24 hours after injury between 3 mm and 
7 mm stretch. From left to right, the first 6 bands in each blot correspond to astrocytes injured at 
0 (control), 3, 4, 5 , 6, and 7 mm of stretch respectively. The 7th band in both blots is a repeat of 
the control sample, and in blot (a) the 8th band is a repeat of 6 mm and in blot (b) it is a repeat of 
5 mm. Both blots were exposed for 30 seconds. Blot (a) is from 1/16/09 plate #1 and blot (b) is 
from 1/16/09 plate #2.
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(a) (b)
In both blots (a) and (b) at 48 hours, all of the bands within in each blot appear very 
similar to one another and it is not possible to detect the subtle differences with the unaided eye.
(a) (b)
Fig. 2. Western blots of GFAP expression in astrocytes 48 hours after injury between 3 mm and 
7 mm stretch. From left to right, the first 6 bands in each blot correspond to astrocytes injured at 
0 (control), 3, 4, 5, 6, and 7 mm of stretch respectively. The 7th band in both blots is a repeat of 
the control sample, and in blot (a) the 8th band is a repeat of 6 mm and in blot (b) it is a repeat of 
7 mm. Both blots were exposed for 15 seconds. Blot (a) is from 1/16/09 plate #5 and blot (b) is 
from 1/16/09 plate #6.
Immunofluorescence
Since GFAP is an intermediate filament that helps to provide astrocytes their shape, the 
fluorescent green-stained GFAP can be used to determine cell morphology alteration after injury. 
As would be expected, GFAP is everywhere in the cell except for the nucleus which shows up as 
a circular black area in the middle of the cell. The uninjured control astrocytes (Fig. 3a.) have a 
circular morphology with several processes. At the mild injury levels of 3 mm and 4 mm of 
stretch (Fig. 3b and c), the astrocytes increase the lengths and numbers of their processes. At the 
moderate levels of 5 mm and 6 mm of stretch (Fig. 3d and e), the processes become even more 
prominent and take on a stringy appearance. These cells are also more difficult to bring into 
focus under the microscope because they are not as flat as the uninjured and mildly injured cells
C 3 4 5 6 7 C 6 C 3 4 5 6 7 C 7
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potentially due to swelling. At the severe injury level of 7 mm of stretch (Fig. 3f), the astrocytes 
have the elongated, more numerous processes, but there are also areas where astrocytes are 
absent. This is most likely due to astrocytes having been detached from the bottom of the Flex 
Plate due to the magnitude of the stretch and then being washed away in the cell fixing process.
Fig. 3. Astrocyte response to injury levels at 24 hours. The astrocytes in picture (a) are 
uninjured controls. The cells in (b) and (c) were injured at a mild level of stretch (3 mm and 4 
mm respectively), the cells in (d) and (e) were injured at moderate levels of stretch (5 mm and 6 





2. Astrocyte Response at Time Points after Injury 
Western Blotting
The Western blots for GFAP expression at times after injury also showed bands right 
above the 51 kDa molecular weight marker which is indicative of GFAP. There was also only 
one band per sample. In Fig. 4 blot (b) bands are missing for the lanes containing the samples 
for the first run of the control, 15 minutes, and the second run of the control. In Fig. 4, blot (a) 
shows a noticeably larger band at the 6 hour mark indicating increased GFAP expression but the 
rest of the bands look very similar to each other. In blot (b) it appears that the band at 24 hours 
after injury is the largest.
(a) (b)
Fig. 4. Western blots of GFAP expression in astrocytes at times between 0.25 and 48 hours after 
injury of 6 mm. From left to right, the first 6 bands in each blot correspond to astrocytes at times 
of N/A (control), 0.25, 2, 6, 24, and 48 hours after injury respectively. The 7th band in both blots 
is a repeat of the control sample, and in blot (a) the 8th band is a repeat of 24 hours and in blot (b) 
it is a repeat of 6 hours. Both blots were exposed for 15 seconds. Blot (a) is from 1/17/09 plate 
#1 and blot (b) is from 1/17/09 plate #2.
Immunofluorescence
As in the control astrocytes from the injury response, the uninjured astrocytes of the time 
course also have a circular morphology with a limited number and length of processes. At 15
C 15 2 6 24 48 C 24 C 15 2 6 24 48 C 6
27
minutes post-injury (Fig. 5b) the astrocytes do not show any characteristics of reactive 
astrocytes. However, by 2 and 6 hours after injury (Fig. 5c and d) they show elongated and 
stringy processes, and also areas with thickened processes which is also characteristic of reactive 
astrocytes. At 24 hours post-injury (Fig. 5e) the astrocytes continue to have stringy and thick 
processes. By 48 hours the processes are not as prominent and cell division is apparent as two 
nuclei are seen in many of the cell bodies.
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Fig. 5. Astrocyte injury response time course at 6 mm. The astrocytes in picture (a) are 
uninjured controls. The cells in (b) have recovered from injury for 15 minutes. The cells in (c) 
and (d) have recovered for 2 hours and 6 hours respectively, and the cells in (e) and (f) have 
recovered for 24 hours and 48 hours respectively.
Discussion
In Western blotting on SDS-PAGE gels, it is known that GFAP runs at approximately 55 kDa, 
and sometimes an additional band at 48 kDa can be seen which results from a breakdown 





blots, it can be concluded that the primary antibody used selectively stained for GFAP due to the 
bands appearing at approximately 55 kDa and the absence of any other bands on the blot, 
including break-down products. GFAP was present in all of the samples except time course blot 
(b) lanes containing the first control, 15 minutes after injury, and the second control. This is 
most likely due to a mistake that was made during protein isolation when RIPA buffer was put 
on the cells in the control and 15 minute wells too early and then discarded. There was also very 
low GFAP expression in the injury level response at 24 hours on blot (a) in the lanes containing 
the samples for 7 mm and the second control, and on blot (b) in the lanes containing the samples 
for 6 mm and 7 mm. This cannot be due to decreased GFAP levels in the samples loaded 
because in blot (a) the lane containing the second run of the control is the same control that was 
loaded in the first lane, which is much darker. There are several explanations for these light 
bands such as incomplete loading of the protein sample, but the cause is unknown. The sizes of 
the bands within each blot are very similar to each other, particularly in figure 2, which makes it 
difficult to determine differences in GFAP expression between the treatments.
For the samples that did show GFAP expression, it was difficult to analyze the amount of 
GFAP in each control and injured sample as the bands were all relatively similar in size to each 
other. This is probably due to the fact that GFAP is a relatively highly expressed protein in 
uninjured astrocytes, therefore making it more difficult to detect subtle changes in its expression. 
In the future, it would be beneficial to analyze the pixel density of the bands using computer 
software, and also to increase the number of replications.
From the immunofluorescence results it can be concluded that GFAP expression showed 
that astrocytes became more reactive with increasing magnitudes of stretch. This is supported by 
the increased number of astrocytic processes, the increased “stringyness” of the processes, the
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thick bundles of GFAP, and the swelling of the astrocytes which was found as they were difficult 
to focus on as they were not in a single plane. The injury response data in the current study 
correlates with the findings of Ellis et al. (1995). Using the same stretch model of injury, Ellis 
and colleagues found that astrocyte injury was proportional to the degree of stretch as evidenced 
by cell morphology seen using electron microscopy, lactate dehydrogenase (LDH) enzyme 
release, and propidium iodide dye exclusion (1995). They found that at a moderate level of 
stretch (5.7 mm), the cells appeared swollen, exhibited structural abnormalities in their 
mitochondria, and had isolated vacuolization in the Golgi apparatus and rough endoplasmic 
reticulum. At increasing levels of stretch, the cells retracted and became stellate which is an 
indication of cytoskeletal disruption. At 7.5 and 8.6 mm of stretch, the cells were retracted with 
intercellular spaces in addition to the other abnormalities but at a more dramatic level of 
expression. (Ellis et al., 1995)
For the time course of GFAP expression after injury at 6 mm of stretch, our 
immunofluorescence data shows that change in astrocyte morphology begins around 2 hours 
post-injury and continues through 48 hours post-injury. The astrocytes display increased number 
of processes between 2 and 24 hours but have a reduced number of processes at 48 hours. Also, 
at 24 hours post-injury astrocyte cell division is seen and this is even more pronounced at 48 
hours after injury. In the study by Ellis and colleagues (1995), it was found that astrocyte 
recovery after injury was dependent on the level at which they were injured. They discovered 
that cells injured at low levels of stretch began to recover as soon as 2 hours after injury and 
were able to completely exclude propidium iodide at 24 hours which shows that their cell 
membranes had regained function. At the more severe levels of stretch (7.5 and 8.6 mm), the 
cells did not begin to recover until 6 hours post-injury, and at 8.6 mm of stretch, the astrocytes
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had not even reached 50% recovery by 24 hours after injury. However, these severely injured 
cells were able to repair themselves to look like the control cells by 2-3 days post-injury. (Ellis et 
al., 1995)
In addition to animal studies, human studies have also been conducted in order to 
determine astrocytic response to traumatic brain injury. In humans with cerebral contusions, 
electron microscopy of brain tissue has shown evidence of astrocytic swelling as early as 3 hours 
post-injury, lasting up to 3 days after injury (Zhao et al., 2003). Human research has also 
focused on GFAP levels in cerebrospinal fluid (CSF) and serum following brain injury. Glial 
fibrillary acidic protein is a good marker of traumatic brain injury as it was found that “GFAP is 
not released after multiple traumas without brain injury” having occurred (Nylen et al., 2006). 
Other proteins expressed following brain injury such as S-100 β have been used as markers of 
TBI, but this protein is also elevated in peripheral trauma and therefore is a less specific 
indicator. Studies first showed that acute CNS injury significantly increased CSF-GFAP levels, 
and astrogliosis increased CSF-GFAP levels but by a lesser degree. However, obtaining CSF 
from brain-injured patients is potentially dangerous and usually contraindicated. Therefore, 
several studies were conducted where serum was collected instead of CSF, and it was found that 
increased levels of GFAP were present in the serum after injury, which is probably due to a 
damaged blood-brain barrier that allows GFAP to enter the systemic circulation. (Nylen et al., 
2006)
In healthy, uninjured individuals, the average serum-GFAP level is only 0.061 pl/L. In a 
study conducted by Nylen and colleagues (2006), serum-GFAP levels were measured in 
individuals with severe TBI, and it was found that those with unfavorable outcomes (death, 
vegetative state, or severe disability) exhibited median GFAP serum levels of 2.72 µg/L which
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was significantly higher than those with favorable outcomes (moderate disability or good 
recovery), who had median GFAP serum levels of 0.85 µg/L. This study found that the highest 
GFAP serum levels usually occurred by day 1 and in no case later than day 4, and then they 
gradually declined. After one year, serum-GFAP levels were normalized in all cases except for 3 
patients who had slightly elevated levels. This research is clinically beneficial as “there is a 
possibility to predict death or unfavorable outcome in patients with extremely elevated serum- 
GFAP levels.” (Nylen et al., 2006)
New, clinically significant findings will only continue if further research is conducted in 
both the therapeutic and cellular areas of TBI. Future work in the present study includes 
quantifying the Western blots, testing the time course of injury response at other levels of stretch, 
and lengthening the duration of time course observations. The astrocytes in our model were kept 
in growth media after injury which does not factor in the effects of secondary insult such as 
hypoxia or ischemia which frequently occur after injury and have significant effects on neural 
tissue. In the future it would be interesting to observe the effects of hypoxia on GFAP 
expression in astrocytes by altering the post-injury environment. Ellis and colleagues (1995) 
have also suggested that the rate of cell stretch is an important determinant in the degree of cell 
injury and another possible research area of interest.
Much remains unknown about the consequences of traumatic brain injury at the cellular 
level and how these events influence patient outcome. This is especially true of the response of 
astrocytes and their interaction with neurons post-injury since this has not become a research 
focus until recent years. The stretch-injury model is a good way to learn more about these 
responses as it mimics the major biomechanical aspects of traumatic brain injury, and allows for 
easy observation of in vitro cell response. This model allows researchers to observe the injury
33
response of one cell type such as astrocytes, or the interaction between multiple cell types such 
as astrocyte-neuronal co-cultures. The stretch-induced injury model also allows researchers to 
manipulate many variables such as the duration and magnitude of stretch injury, and post-injury 
conditions such as oxygen deprivation. Through research directed at elucidating the normal roles 
of astrocytes and their roles in response to injury, knowledge can be amassed that can lead to 
drug development targeting specific mechanisms. Since there are not any highly successful drug 
therapies to treat traumatic brain injury, both cellular and therapeutic research must be continued 
in order to better understand and hopefully successfully treat traumatic brain injury.
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B. Protein Concentration Calculations
C. Proteins for Western Blots
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3Appendix B
Protein Concentrations for 1/16/09 Plates #1, 2, 5, & 6 and 1/17/09 Plates #1 & 2
Standards
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1/16/09 P lates ■
Plate #1: Control @  24 hr 0.236 11.474 2.29 0.44 0.87 1.09 2.18 4.36
Plate #1: 3mm @  24 hr 0.121 5.484 1.10 0.91 1.82 2.28 4.56 9.12
Plate #1: 4mm @  24 hr 0.175 8 .297 1.66 0.60 1.21 1.51 3.01 6.03
Plate #1: 5mm @  24 hr 0.168 7.932 1.59 0.63 1.26 1.58 3.15 6.30
Plate #1: 6mm @  24 hr 0.068 2.724 0.54 1.84 3.67 4.59 9.18 18.36
Plate #1: 7mm @  24 hr 0.160 7.516 1.50 0.67 1.33 1.66 3.33 6.65
Plate #2: Control @  24 hr 0.100 4.391 0.88 1.14 2.28 2.85 5.69 11.39
Plate #2: 3mm @  24 hr 0.153 7.151 1.43 0.70 1.40 1.75 3.50 6.99
Plate #2: 4mm @  24 hr 0.168 7.932 1.59 0.63 1.26 1.58 3.15 6.30
Plate #2: 5mm @  24 hr 0.137 6.318 1.26 0.79 1.58 1.98 3.96 7.91
Plate #2: 6mm @  24  hr 0.185 8.818 1.76 0.57 1.13 1.42 2.84 5.67
Plate #2: 7mm @  24 hr 0.177 8.401 1.68 0.60 1.19 1.49 2.98 5.95
Plate #5: Control @  48 hr 0.163 7.672 1.53 0.65 1.30 1.63 3.26 6.52
Plate #5: 3mm @  48 hr 0.210 10.120 2.02 0.49 0.99 1.24 2.47 4.94
Plate #5: 4mm @  48 hr 0.190 9.078 1.82 0.55 1.10 1.38 2.75 5.51
Plate #5: 5mm @  48  hr 0.188 8.974 1.79 0.56 1.11 1.39 2.79 5.57
Plate #5: 6mm @  48 hr 0.204 9.807 1.96 0.51 1.02 1.27 2.55 5.10
Plate #5: 7mm @  48 hr 0.254 12.411 2.48 0.40 0.81 1.01 2.01 4.03
Plate #6: Control @  48 hr 0.214 10.328 2.07 0.48 0.97 1.21 2.42 4.84
Plate #6: 3mm @  48 hr 0.261 12.776 2.56 0.39 0.78 0.98 1.96 3.91
Plate #6: 4mm @  48 hr 0.210 10.120 2.02 0.49 0.99 1.24 2.47 4.94
Plate #6: 5mm @  48 hr 0.216 10.432 2.09 0.48 0.96 1.20 2.40 4.79
Plate #6: 6mm @  48 hr 0.229 11.109 2.22 0.45 0.90 1.13 2.25 4.50
Plate #6: 7mm @  48 hr 0.229 11.109 2.22 0.45 0.90 1.13 2.25 4.50
1/17/09 P lates
*
Plate #1: Control @  6mm 0.214 10.328 2.07 0.48 0.97 1.21 2.42 4.84
Plate #1: 0.25 hr @  6mm 0.219 10.589 2.12 0.47 0.94 1.18 2.36 4.72
Plate #1: 2 hr @  6mm 0.239 11.630 2.33 0.43 0.86 1.07 2.15 4.30




















y = 0.0192x + 0.0157
R2 = 0.9455
0 10 20 30 40 50 60 70
Protein Concentration (ug/ml)
4Plate #1: 24 hr @  6mm 0.166 7.828 1.57 0.64 1.28 1.60 3.19 6.39
Plate #1: 48 hr @  6mm 0.228 11.057 2.21 0.45 0.90 1.13 2.26 4.52
Plate #2: Control @  6mm 0.148 6.891 1.38 0.73 1.45 1.81 3.63 7.26
Plate #2: 0.25 hr @  6mm 0.153 7.151 1.43 0.70 1.40 1.75 3.50 6.99
Plate #2: 2 hr @  6mm 0.220 10.641 2.13 0.47 0.94 1.17 2.35 4.70
Plate #2: 6 hr @  6mm 0.214 10.328 2.07 0.48 0.97 1.21 2.42 4.84
Plate #2: 24 hr @  6mm 0.212 10.224 2.04 0.49 0.98 1.22 2.45 4.89
Plate #2: 48 hr @  6mm 0.202 9.703 1.94 0.52 1.03 1.29 2.58 5.15
5Protein Concentrations for 2/18/09 Plates #1 & 2 and 2/24/09 Plates #1 & 3
S tandards A bsorbance
(ug/m l) (595 nm)























Plate #1: Control @  24 hr 0.093 4.084 0.82 1.22 2.45 3.06 6.12 12.24
Plate #1: 3mm @  24 hr 0.136 6.213 1.24 0.80 1.61 2.01 4.02 8.05
Plate #1: 4mm @  24 hr 0.218 10.272 2.05 0.49 0.97 1.22 2.43 4.87
Plate #1: 5mm @  24 hr 0.215 10.124 2.02 0.49 0.99 1.23 2.47 4.94
Plate #1: 6mm @  24 hr 0.161 7.450 1.49 0.67 1.34 1.68 3.36 6.71
Plate #1: 7mm @  24 hr 0.153 7.054 1.41 0.71 1.42 1.77 3.54 7.09
Plate #2: Control @  24 hr 0.194 9.084 1.82 0.55 1.10 1.38 2.75 5.50
Plate #2: 3mm @  24 hr 0.196 9.183 1.84 0.54 1.09 1.36 2.72 5.44
Plate #2: 4mm @  24 hr 0.194 9.084 1.82 0.55 1.10 1.38 2.75 5.50
Plate #2: 5mm @  24 hr 0.198 9.282 1.86 0.54 1.08 1.35 2.69 5.39
Plate #2: 6mm @  24 hr 0.207 9.728 1.95 0.51 1.03 1.28 2.57 5.14
Plate #2: 7mm @  24 hr 0.219 10.322 2.06 0.48 0.97 1.21 2.42 4.84
2/24/09 Plates
Plate #1: Control @  6mm 0.167 7.748 1.55 0.65 1.29 1.61 3.23 6.45
Plate #1: 15 min. @  6mm 0.212 9.975 2.00 0.50 1.00 1.25 2.51 5.01
Plate #1: 2 hr @  6mm 0.198 9.282 1.86 0.54 1.08 1.35 2.69 5.39
Plate #1: 6 hr @  6mm 0.233 11.015 2.20 0.45 0.91 1.13 2.27 4.54
Plate #1: 24 hr @  6mm 0.224 10.569 2.11 0.47 0.95 1.18 2.37 4.73
Plate #1: 48 hr @  6mm 0.217 10.223 2.04 0.49 0.98 1.22 2.45 4.89
Plate #3: Control @  6.5mm 0.223 10.520 2.10 0.48 0.95 1.19 2.38 4.75
Plate # 3 :1 5  min @  6.5mm 0.211 9.926 1.99 0.50 1.01 1.26 2.52 5.04
Plate #3: 2 hr @  6.5mm 0.213 10.025 2.00 0.50 1.00 1.25 2.49 4.99
Plate #3: 6 hr @  6.5mm 0.214 10.074 2.01 0.50 0.99 1.24 2.48 4.96
Plate #3: 24 hr @  6.5mm 0.192 8.985 1.80 0.56 1.11 1.39 2.78 5.56
Plate #3: 48 hr @  6.5mm 0.188 8.787 1.76 0.57 1.14 1.42 2.85 5.69
Standard Curve





















6Calculations for Western Blot Samples
A p p en d ix  C
Well Sample ID Sample (ul) dH2O (ul) Loading Buffer (ul) Reducing Agent (ul)
1 S T D 0 .0 0 0 .0 0 0 .0 0 0 .00
2 1 /1 6 /0 9  P la te  #1: Contro l @  2 4  hr 1 .09 15.11 6 .3 0 2 .5 0
3 1 /1 6 /0 9  P late  #1: 3 m m  @  2 4  hr 2 .2 8 1 3 .9 2 6 .3 0 2 .5 0
4 1 /1 6 /0 9  P late  #1: 4 m m  @  2 4  hr 1.51 1 4 .6 9 6 .3 0 2 .5 0
5 1 /1 6 /0 9  P late  #1: 5m m  @  2 4  hr 1 .58 1 4 .6 2 6 .3 0 2 .5 0
6 1 /1 6 /0 9  P la te  #1: 6 m m  @  2 4  hr 4 .5 9 11.61 6 .3 0 2 .5 0
7 1 /1 6 /0 9  P late  #1: 7 m m  @  2 4  hr 1 .66 1 4 .5 4 6 .3 0 2 .5 0
8 1 /1 6 /0 9  P late  #1: Contro l @  2 4  hr 1 .09 15.11 6 .3 0 2 .5 0
9 1 /1 6 /0 9  P late  #1: 6 m m  @  2 4  hr 4 .5 9 11.61 6 .3 0 2 .5 0
10 S T D 0 .0 0 0 .0 0 0 .0 0 0 .00
Well Sample ID Sample (ul) dH2O (ul) Loading Buffer (ul) Reducing Agent (ul)
1 S T D 0 .0 0 0 .0 0 0 .0 0 0 .00
2 1 /1 6 /0 9  P late  #2: C ontro l @  2 4  hr 2 .8 5 1 3 .3 5 6 .3 0 2 .5 0
3 1 /1 6 /0 9  P late  #2: 3m m  @  2 4  hr 1 .75 1 4 .4 5 6 .3 0 2 .5 0
4 1 /1 6 /0 9  P late  #2: 4 m m  @  2 4  hr 1 .58 1 4 .6 2 6 .3 0 2 .5 0
5 1 /1 6 /0 9  P late  #2: 5 m m  @  2 4  hr 1 .98 1 4 .2 2 6 .3 0 2 .5 0
6 1 /1 6 /0 9  P late  #2: 6 m m  @  2 4  hr 1 .42 1 4 .7 8 6 .3 0 2 .5 0
7 1 /1 6 /0 9  P late  #2: 7 m m  @  2 4  hr 1 .49 14.71 6 .3 0 2 .5 0
8 1 /1 6 /0 9  P late  #2: Contro l @  2 4  hr 2 .8 5 1 3 .3 5 6 .3 0 2 .5 0
9 1 /1 6 /0 9  P la te  #2: 5 m m  @  2 4  hr 1 .98 1 4 .2 2 6 .3 0 2 .5 0
10 S T D 0 .0 0 0 .0 0 0 .0 0 0 .00
Well Sample ID Sample (ul) dH2O (ul) Loading Buffer (ul) Reducing Agent (ul)
1 S T D 0 .0 0 0 .0 0 0 .0 0 0 .00
2 1 /1 6 /0 9  P late  #5: Control @  4 8  hr 1 .63 1 4 .5 7 6 .3 0 2 .5 0
3 1 /1 6 /0 9  P la te  #5: 3 m m  @  4 8  hr 1 .24 1 4 .9 6 6 .3 0 2 .5 0
4 1 /1 6 /0 9  P late  #5: 4 m m  @  4 8  hr 1 .38 1 4 .8 2 6 .3 0 2 .5 0
5 1 /1 6 /0 9  P late  #5: 5 m m  @  4 8  hr 1 .39 14.81 6 .3 0 2 .5 0
6 1 /1 6 /0 9  P late  #5: 6 m m  @  4 8  hr 1 .27 1 4 .9 3 6 .3 0 2 .5 0
7 1 /1 6 /0 9  P late  #5: 7 m m  @  4 8  hr 1.01 1 5 .1 9 6 .3 0 2 .5 0
8 1 /1 6 /0 9  P late  #5: Contro l @  4 8  hr 1 .63 1 4 .5 7 6 .3 0 2 .5 0
9 1 /1 6 /0 9  P late  #5: 6 m m  @  4 8  hr 1 .27 1 4 .9 3 6 .3 0 2 .5 0
10 S T D 0 .0 0 0 .0 0 0 .0 0 0 .0 0
Well Sample ID Sample (ul) dH2O (ul) Loading Buffer (ul) Reducing Agent (ul)
1 S T D 0 .0 0 0 .0 0 0 .0 0 0 .0 0
2 1 /1 6 /0 9  P la te  #6: Contro l @  4 8  hr 1.21 1 4 .9 9 6 .3 0 2 .5 0
3 1 /1 6 /0 9  P la te  #6: 3 m m  @  4 8  hr 0 .9 8 1 5 .2 2 6 .3 0 2 .5 0
74 1 /1 6 /0 9  P late  #6: 4 m m  @  4 8  hr 1 .24 1 4 .9 6 6 .3 0 2 .5 0
5 1 /1 6 /0 9  P la te  #6: 5 m m  @  4 8  hr 1 .20 1 5 .0 0 6 .3 0 2 .5 0
6 1 /1 6 /0 9  P late  #6: 6 m m  @  4 8  hr 1 .13 1 5 .0 7 6 .3 0 2 .5 0
7 1 /1 6 /0 9  P late  #6: 7m m  @  4 8  hr 1 .13 1 5 .0 7 6 .3 0 2 .5 0
8 1 /1 6 /0 9  P late  #6: C ontrol @  4 8  hr 1.21 1 4 .9 9 6 .3 0 2 .5 0
9 1 /1 6 /0 9  P late  #6: 7 m m  @  4 8  hr 1 .13 1 5 .0 7 6 .3 0 2 .5 0
10 S T D 0 .0 0 0 .0 0 0 .0 0 0 .0 0
Well Sample ID Sample (ul) dH2O (ul) Loading Buffer (ul) Reducing Agent (ul)
1 S T D 0 .0 0 0 .0 0 0 .0 0 0 .0 0
2 1 /1 7 /0 9  P late  #1: Contro l @  6 m m 1.21 1 4 .9 9 6 .3 0 2 .5 0
3 1 /1 7 /0 9  P late  #1: 0 .2 5  hr @  6 m m 1.18 1 5 .0 2 6 .3 0 2 .5 0
4 1 /1 7 /0 9  P late  #1: 2  hr @  6m m 1.07 1 5 .1 3 6 .3 0 2 .5 0
5 1 /1 7 /0 9  P late  #1: 6  hr @  6 m m 9 .88 6 .3 2 6 .3 0 2 .5 0
6 1 /1 7 /0 9  P late  #1: 2 4  hr @  6m m 1.60 1 4 .6 0 6 .3 0 2 .5 0
7 1 /1 7 /0 9  P late  #1: 4 8  hr @  6 m m 1.13 1 5 .0 7 6 .3 0 2 .5 0
8 1 /1 7 /0 9  P late  #1: C ontrol @  6 m m 1.21 1 4 .9 9 6 .3 0 2 .5 0
9 1 /1 7 /0 9  P la te  #1: 2 4  hr @  6 m m 1.60 1 4 .6 0 6 .3 0 2 .5 0
10 S T D 0 .0 0 0 .0 0 0 .0 0 0 .0 0
Well Sample ID Sample (ul) dH2O (ul) Loading Buffer (ul) Reducing Agent (ul)
1 S T D 0 .0 0 0 .0 0 0 .0 0 0 .0 0
2 1 /1 7 /0 9  P late  #2: C ontrol @  6 m m 1.81 1 4 .3 9 6 .3 0 2 .5 0
3 1 /1 7 /0 9  P late  #2: 0 .2 5  hr @  6 m m 1 .75 1 4 .4 5 6 .3 0 2 .5 0
4 1 /1 7 /0 9  P late  #2: 2  hr @  6 m m 1.17 1 5 .0 3 6 .3 0 2 .5 0
5 1 /1 7 /0 9  P la te  #2: 6  hr @  6 m m 1.21 1 4 .9 9 6 .3 0 2 .5 0
6 1 /1 7 /0 9  P la te  #2: 2 4  hr @  6 m m 1.22 1 4 .9 8 6 .3 0 2 .5 0
7 1 /1 7 /0 9  P la te  #2: 4 8  hr @  6 m m 1 .29 14.91 6 .3 0 2 .5 0
8 1 /1 7 /0 9  P late  #2: Contro l @  6 m m 1.81 1 4 .3 9 6 .3 0 2 .5 0
9 1 /1 7 /0 9  P late  #2: 6  hr @  6m m 1.21 1 4 .9 9 6 .3 0 2 .5 0
10 S T D 0 .0 0 0 .0 0 0 .0 0 0 .0 0
Well Sample ID Sample (ul) dH2O (ul) Loading Buffer (ul) Reducing Agent (ul)
1 S T D 0 .0 0 0 .0 0 0 .0 0 0 .0 0
2 2 /1 8 /0 9  P late  #1: C ontrol @  2 4  hr 3 .0 6 1 3 .1 4 6 .3 0 2 .5 0
3 2 /1 8 /0 9  P late  #1: 3m m  @  2 4  hr 2.01 1 4 .1 9 6 .3 0 2 .5 0
4 2 /1 8 /0 9  P late  #1: 4 m m  @  2 4  hr 1 .22 1 4 .9 8 6 .3 0 2 .5 0
5 2 /1 8 /0 9  P late  #1: 5m m  @  2 4  hr 1 .23 1 4 .9 7 6 .3 0 2 .5 0
6 2 /1 8 /0 9  P late  #1: 6 m m  @  2 4  hr 1 .68 1 4 .5 2 6 .3 0 2 .5 0
7 2 /1 8 /0 9  P late  #1: 7 m m  @  2 4  hr 1 .77 1 4 .4 3 6 .3 0 2 .5 0
8 2 /1 8 /0 9  P late  #1: Control @  2 4  hr 3 .0 6 1 3 .1 4 6 .3 0 2 .5 0
9 2 /1 8 /0 9  P late  #1 : 5m m  @  2 4  hr 1 .23 1 4 .9 7 6 .3 0 2 .5 0
10 S T D 0 .0 0 0 .0 0 0 .0 0 0 .0 0
8Well Sample ID Sample (ul) dH2O (ul) Loading Buffer (ul) Reducing Agent (ul)
1 S T D 0 .0 0 0 .0 0 0 .0 0 0 .0 0
2 2 /1 8 /0 9  P late  #2: Contro l @  2 4  hr 1 .38 1 4 .8 2 6 .3 0 2 .5 0
3 2 /1 8 /0 9  P late  #2: 3 m m  @  2 4  hr 1 .36 1 4 .8 4 6 .3 0 2 .5 0
4 2 /1 8 /0 9  P late  #2: 4 m m  @  2 4  hr 1 .38 1 4 .8 2 6 .3 0 2 .5 0
5 2 /1 8 /0 9  P late  #2 : 5m m  @  2 4  hr 1 .35 1 4 .8 5 6 .3 0 2 .5 0
6 2 /1 8 /0 9  P late  #2: 6 m m  @  2 4  hr 1 .28 1 4 .9 2 6 .3 0 2 .5 0
7 2 /1 8 /0 9  P late  #2: 7 m m  @  2 4  hr 1.21 1 4 .9 9 6 .3 0 2 .5 0
8 2 /1 8 /0 9  P late  #2: Contro l @  2 4  hr 1 .38 1 4 .8 2 6 .3 0 2 .5 0
g 2 /1 8 /0 9  P late  #2: 6 m m  @  2 4  hr 1 .28 1 4 .9 2 6 .3 0 2 .5 0
10 S T D 0 .0 0 0 .0 0 0 .0 0 0 .0 0
Well Sample ID Sample (ul) dH2O (ul) Loading Buffer (ul) Reducing Agent (ul)
1 S T D 0 .0 0 0 .0 0 0 .0 0 0 .0 0
2 2 /2 4 /0 9  P la te  #1: Contro l @  6 m m 1.61 1 4 .5 9 6 .3 0 2 .5 0
3 2 /2 4 /0 9  P late  # 1 : 1 5  min. @  6 m m 1.25 1 4 .9 5 6 .3 0 2 .5 0
4 2 /2 4 /0 9  P late  #1 : 2  hr @  6 m m 1.35 1 4 .8 5 6 .3 0 2 .5 0
5 2 /2 4 /0 9  P late  #1: 6  hr @  6 m m 1.13 1 5 .0 7 6 .3 0 2 .5 0
6 2 /2 4 /0 9  P late  #1: 2 4  hr @  6 m m 1.18 1 5 .0 2 6 .3 0 2 .5 0
7 2 /2 4 /0 9  P late  #1: 4 8  hr @  6 m m 1.22 1 4 .9 8 6 .3 0 2 .5 0
8 2 /2 4 /0 9  P la te  #1: C ontrol @  6m m 1.61 1 4 .5 9 6 .3 0 2 .5 0
9 2 /2 4 /0 9  P la te  #1: 6  hr @  6 m m 1.13 1 5 .0 7 6 .3 0 2 .5 0
10 S T D 0 .0 0 0 .0 0 0 .0 0 0 .00
Well Sample ID Sample (ul) dH2O (ul) Loading Buffer (ul) Reducing Agent (ul)
1 S T D 0 .0 0 0 .0 0 0 .0 0 0 .0 0
2 2 /2 4 /0 9  P late  #3: Control @  6 .5 m m 1 .19 15.01 6 .3 0 2 .5 0
3 2 /2 4 /0 9  P late  #3: 15 min @  6 .5 m m 1.26 1 4 .9 4 6 .3 0 2 .5 0
4 2 /2 4 /0 9  P late  #3: 2  hr @  6 .5 m m 1.25 1 4 .9 5 6 .3 0 2 .5 0
5 2 /2 4 /0 9  P late  #3: 6  hr @  6 .5 m m 1.24 1 4 .9 6 6 .3 0 2 .5 0
6 2 /2 4 /0 9  P late  #3: 2 4  hr @  6 .5 m m 1.39 14.81 6 .3 0 2 .5 0
7 2 /2 4 /0 9  P late  #3: 4 8  hr @  6 .5 m m 1.42 1 4 .7 8 6 .3 0 2 .5 0
8 2 /2 4 /0 9  P la te  #3: Control @  6 .5 m m 1.19 15.01 6 .3 0 2 .5 0
9 2 /2 4 /0 9  P late  #3: 2  hr @  6 .5 m m 1.25 1 4 .9 5 6 .3 0 2 .5 0
10 S T D 0 .0 0 0 .0 0 0 .0 0 0 .0 0
